3 transcripts
LCTX
Earnings call transcript
NYSEAMERICAN
2024 Q1
9 May 24
points. First, we announced additional validating data this week, which offers implications for both the clinical benefit and durability of our lead
LCTX
Earnings call transcript
NYSEAMERICAN
2023 Q4
7 Mar 24
of CYFOVRI. So the CHMP issued a negative opinion attributable to the lack of a functional benefit.
And when I look at the recent data that was reported
LCTX
Earnings call transcript
NYSEAMERICAN
2023 Q2
10 Aug 23
but serious side effect is exactly the sort of thing that can derail a product when it only offers a small clinical benefit. As we all know, the clinical
- Prev
- 1
- Next